Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients
Hoth Therapeutics, Inc. (HOTH)
Company Research
Source: PR Newswire
NEW YORK, Jan. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate preclinical studies of HT-001, a topical formulation designed for the treatment of patients with rash and skin disorders associated with initial and repeat EGFR inhibitor cancer treatment. Together with Charles River Laboratories, Hoth has outlined six preclinical studies, the first bioanalytical method development studies beginning in Q1 2021. The initial studies will develop the required bioanalytical methods to perform GLP toxicology studies required by the U.S. Food and Drug Administration (FDA) to initiate clinical studies for HT-001. Hoth recently submitted a request for a Pre-Investigational New Drug (IND) meeting to the FDA to discuss the proposed drug development program of HT-001 which is also anticipated to occur during the first quarter of 2021. At the Pre-IND Meeting, Hoth will discuss the req
Show less
Read more
Impact Snapshot
Event Time:
HOTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOTH alerts
High impacting Hoth Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOTH
News
- Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
- Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds [Yahoo! Finance]Yahoo! Finance
- Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross ProceedsPR Newswire
- Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment [Yahoo! Finance]Yahoo! Finance
- Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity TreatmentPR Newswire
HOTH
Sec Filings
- 4/22/24 - Form 424B3
- 4/22/24 - Form EFFECT
- 4/11/24 - Form S-1
- HOTH's page on the SEC website